Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1 (currently amended) A method for [preventing or] treating bipolar disorder comprising administering to a subject in need thereof a therapeutically effective amount of an enantiomer of Formula (I) or enantiomeric mixture wherein one enantiomer of Formula (I) predominates:

$$R_{4}$$
 R_{1}
Formula (I)

wherein

phenyl is substituted at X with one to five halogen atoms selected from the group consisting of fluorine, chlorine, bromine and iodine; and,

R₁, R₂, R₃ and R₄ are independently selected from the group consisting of hydrogen and C₁-C₄ alkyl; wherein C₁-C₄ alkyl is optionally substituted with phenyl (wherein phenyl is optionally substituted with substituents independently selected from the group consisting of halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, amino, nitro and cyano).

Claim 2 (original) The method of claim 1 wherein X is chlorine.

Claim 3 (original) The method of claim 1 wherein X is substituted at the ortho position of the phenyl ring.

Claim 4 (original) The method of claim 1 wherein R₁, R₂, R₃ and R₄ are selected from hydrogen.

Claim 5 (original) The method of claim 1 wherein the enantiomer of Formula (I) is an enantiomer of Formula (Ia):

$$R_3$$
 R_4
 R_1
 R_2
Formula (Ia)

wherein

phenyl is substituted at X with one to five halogen atoms selected from the group consisting of fluorine, chlorine, bromine and iodine; and,

R₁, R₂, R₃ and R₄ are independently selected from the group consisting of hydrogen and C₁-C₄ alkyl; wherein C₁-C₄ alkyl is optionally substituted with phenyl (wherein phenyl is optionally substituted with substituents independently selected from the group consisting of halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, amino, nitro and cyano).

Claim 6 (original) The method of claim 5 wherein X is chlorine.

Claim 7 (original) The method of claim 5 wherein X is substituted at the ortho position of the phenyl ring.

Claim 8 (original) The method of claim 5 wherein R₁, R₂, R₃ and R₄ are selected from hydrogen.

Claim 9 (original) The method of claim 5 wherein the enantiomer of Formula (Ia) predominates to the extent of about 90% or greater.

Claim 10 (original) The method of claim 5 wherein the enantiomer of Formula (Ia) predominates to the extent of about 98% or greater.

Claim 11 (original) The method of claim 1 wherein the enantiomer of Formula (I) is an enantiomer of Formula (Ib):

Claim 12 (original) The method of claim 11 wherein the enantiomer of Formula (Ib) predominates to the extent of about 90% or greater.

Claim 13 (original) The method of claim 11 wherein the enantiomer of Formula (Ib) predominates to the extent of about 98% or greater.

Claim 14 (original) The method of claim 1 wherein bipolar disorder is selected from the group consisting of bipolar disorder type I, bipolar disorder type II, cyclothymic disorder, rapid cycling, ultradian cycling, bipolar depression, acute mania, mania, mixed mania, hypomania and episodes associated with bipolar disorder.

Claim 15 (original) The method of claim 1 wherein the therapeutically effective amount is from about 0.01 mg/Kg/dose to about 100 mg/Kg/dose.

Claim 16 (original) The method of claim 1 wherein the method is a method for slowing or delaying the progression of bipolar disorder comprising administering to a subject in need thereof a therapeutically effective amount of an enantiomer of Formula (I) or enantiomeric mixture wherein one enantiomer of Formula (I) predominates.

Claim 17 (original) The method of claim 16 wherein the therapeutically effective amount is from about 0.01 mg/Kg/dose to about 100 mg/Kg/dose.